Yamasaki T et al. |
Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. |
|
Cell Transplant |
pmid:9710310
|
Huang K et al. |
Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. |
|
Int J Immunopathol Pharmacol |
pmid:22697071
|
Tedesco-Silva H et al. |
FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. |
|
Clin Transplant |
pmid:19719728
|
Sordillo PP et al. |
Review: The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. |
|
In Vivo |
pmid:26546519
|
Suleiman M et al. |
FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. |
|
Transplant. Proc. |
pmid:15808648
|
Yan S et al. |
Control of intestinal allograft rejection by FTY720 and costimulation blockade. |
|
Transplant. Proc. |
pmid:15808565
|
Galvão VR et al. |
Prolonged administration of FTY720 does not cause renal toxicity in mice. |
|
Transplant. Proc. |
pmid:15808564
|
Schmid G et al. |
FTY720 inhibits tumor growth and angiogenesis. |
|
Transplant. Proc. |
pmid:15808563
|
Kataoka H et al. |
Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. |
|
Transplant. Proc. |
pmid:15808562
|
DeAngelis T and Lublin F |
Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. |
|
Mt. Sinai J. Med. |
pmid:18500719
|